Human CTLA4 & IL-2 Reporter Recombinant Cell Line, Jurkat (CAT#: IOC-LX149)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 promoter with constitutive expression of human CTLA4 (Cytotoxic T-Lymphocyte Associated Protein, CD152; GenBank Accession #NM_005214). Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

•Screen for activators or inhibitors of CTLA4 signaling in a cellular context
•Characterize the biological activity of CTLA4 and its interactions with ligands

Human

Jurkat

CTLA4 & IL-2 Reporter

CTLA4, also known as CD152, is a protein receptor that functioning as an immune checkpoint. It is expressed by activated T cells and transmits an inhibitory signal to T cells. CTLA4 is homologous to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. CTLA-4 binds to CD80 and CD86 with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 for its ligands and act as an "off" switch when bound to CD80 or CD86. CTLA-4 is an important immunotherapy target for the treatment of cancer and autoimmune diseases.